Spark's price for Luxturna blindness gene therapy too high: ICER

loading...


Spark’s price for Luxturna blindness gene therapy too high: ICER
(Reuters) – The proposed price for Spark Therapeutics Inc’s groundbreaking one-time gene therapy for a rare form of blindness is far too high, an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday.


Source: Health And Fitness

Reply

Pin It on Pinterest

Shares
Share This
loading...